Preparation and use of compounds as protease inhibitors

摘要

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a bond or -N(R⁵)-; T is a bond, -O-, -C(O)-; S, -N(R⁵)-, or -C(R^6'R^7'); U is a bond or -C(R⁶)(R⁷)- Y is C or N; Z is C or N; ring A, including variables Y and Z, is a three to nine membered cycloalkyl, cycloalkenyl, heterocylcyl, heterocyclenyl, aryl, and heteroaryl ring having 0 to 4, preferably 0 to 2, heteroatoms independently selected from the group consisting of O, S, N and -N(R)-, wherein ring A is unsubstituted or substituted with 1 to 5 independently selected R¹ moieties and/or oxo when ring A is cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl; and R, R¹, R², R³, R⁴, R⁵, R⁶, R⁶, R⁷ and R^7' are as defined in the specification; pharmaceutical compositions comprising the compounds of formula I and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.